- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04251975
Masked Hypertensive Patients With Obstructive Sleep Apnea (Masked-OSA)
Effect of Intervention With Continuous Positive Pressure (CPAP) on Nocturnal Blood Pressure (BP) in Patients With Masked Hypertension and Sleep Apnea
The general objective is to evaluate the effect of continuous positive airway pressure (CPAP) treatment in patients with masked hypertension.
The secondary objectives are: i) To evaluate the prevalence of different circadian patterns of BP in ambulatory blood pressure monitoring (ABPM) (dipper / non-dipper); ii) To assess in these patients the relationship between compliance with CPAP treatment and the response to nocturnal BP; iii) To identify variables of the ABPM, and biomarkers that are related to the unfavourable pattern of nocturnal BP response in these patients treated with CPAP; iv) To evaluate the change in the profile of biomarkers with the treatment.
Methodology: Open, parallel, prospective, randomized and controlled study in which an ABPM will be performed in individuals with masked hypertension referred to the sleep unit and diagnosed of OSA (AHI≥ 30) without sleepiness (Epworth≤18).
A total of 64 subjects with OSA and masked hypertension will be recruited. It will be collected blood for the determination of biomarkers. Subsequently, they will be randomized to receive treatment with CPAP (32) or conservative treatment (32). After 3 months of initiation, ABPM and biological determinations will be repeated.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recruitment: It will be recruited subjects with masked hypertension. For that, normotensive subjects (Blood pressure (BP)<140/90mmHg in the office) referred to the sleep unit of the Hospital Santa Maria (Spain) who are diagnosed of severe OSA (AHI≥30) by a sleep study and who do not present significant somnolence (Epworth≤18) will be proposed to participate in the study. Then, it will be performed an ABPM during-24 hours, and those subjects with an abnormal ABPM results and normal BP in the office will be included, are those subjects called masked hypertensive.
Definition of the groups: Patients will be randomized to receive one of the following treatments:
- CPAP: Patients who will receive CPAP treatment. The CPAP titration will be carried out with an automatic or manual CPAP according to usual clinical practice.
- Conservative treatment: Patients who will receive conservative treatment based on hygienic-dietetic measures.
Randomization: It will be carried out with an automated platform
Duration of the treatment: All patients randomized to CPAP will begin treatment as soon as possible after randomization, and will continue treatment until the study ends (3 months).
Patients who interrupt treatment will be excluded from the study. ABPM and blood sample collection will be performed on all included patients at the beginning of the study and at 3 months under treatment (CPAP or conservative care).
Follow-up: All patients will be evaluated at the beginning of the study, at first month and at three months during the follow-up period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ferran Barbé Illa, MD
- Phone Number: (+34) 97370 53 72
- Email: febarbe.lleida.ics@gencat.cat
Study Locations
-
-
-
Lleida, Spain, 25198
- Hospital Universitari Arnau de Vilanova
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women over 18 years of age
- Referred to the sleep unit for suspected OSA
- Being masked hypertensive and presenting an AHI≥ 30 in the sleep study
- Signature of the informed consent.
Exclusion Criteria:
- Previous CPAP treatment
- Significant somnolence defined by an Epworth Sleepiness Scale (ESS) score higher than 18
- Psychophysical inability to complete questionnaires
- Previous diagnosis or suspicion of another sleep disorder
- Presence of more than 50% of central apneas or Cheyne-Stokes respiration
- Having a serious chronic disease: neoplasia, renal failure, severe chronic obstructive pulmonary disease, chronic depression and other chronic limiting diseases
- Medical history that may interfere with the objectives of the study or, in the opinion of the researcher, may compromise the conclusions
- Any medical, social or geographical factor that may endanger the patient's compliance
- Having a profession of high risk (professional driver).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CPAP treatment
Group of patients who will receive CPAP treatment
|
In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure.
It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
|
No Intervention: Conservative measures
Group of patients who will receive conservative treatment based on hygienic-dietetic measures
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of CPAP treatment on BP in masked hypertensive patients with severe OSA
Time Frame: 3 years
|
Change in mmHg in the blood pressure of the ambulatory blood pressure monitoring parameters after the treatment
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of the different circadian BP patterns (dipper/no-dipper) in the ABPM of masked hypertensive subjects diagnosed with severe OSA without significant somnolence (Epworth≤18)
Time Frame: 3 years
|
The prevalence of each circadian patterns will be calculated from the baseline ambulatory blood pressure monitoring data
|
3 years
|
Association between CPAP use and blood pressure change in ABPM
Time Frame: 3 years
|
The relation between CPAP compliance (hours/night) and changes in mean nighttime BP (mmHg) between baseline and at 3-months in ABPM measurements will be assesed
|
3 years
|
Ambulatory blood pressure parameters that could be related to the response to CPAP treatment
Time Frame: 3 years
|
Using all the ABPM variables we will proceed to the identification of variables that are related to the change in mean nocturnal BP in patients treated with CPAP
|
3 years
|
Changes in the biomarkers' profile (mRNAs) after CPAP treatment
Time Frame: 3 years
|
Using the blood samples obtained in the baseline and 3 months visit it will be evaluated possible changes in the biomarkers profile after CPAP treatment. Learning Phase: complete profile analysis (754 miRNAs) will be carried out in 24 patients Learning Phase: complete profile analysis (754 miRNAs) will be carried out in 24 patients representative of the change in BP in treated patients. The miRNAs associated with the change in BP will be identified from the 754 miRNAs potentially present in serum and plasma. Validation Phase: Specific primers will be designed for the real-time PCR amplification of the genes for which we have found a significant association The miRNAs found will be analyzed after 3 months of treatment. Analysis of biomarkers. Immunoassay techniques will evaluate the following markers before and after treatment: angiotensin I, II and III, plasma renin activity, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and endogenous ouabain. |
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ferran Barbé Illa, MD, CIBERES, SEPAR
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2131-Masked-OSA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
Clinical Trials on CPAP treatment
-
University Hospital, GrenobleCompletedHeart Failure | Sleep Apnea, Obstructive | Arteriosclerosis of Coronary Artery Bypass Graft or Other Coronary ReperfusionFrance
-
Ulysses Magalang MDTerminatedObstructive Sleep ApneaUnited States
-
University Hospital, GrenobleUnknownObstructive Sleep Apnea Syndrome | HypertensionFrance
-
Sociedad Española de Neumología y Cirugía TorácicaSocietat Catalana de PneumologiaRecruitingSleep Apnea, Obstructive | NormotensiveSpain
-
Mario Negri Institute for Pharmacological ResearchCompletedCOVID-19 | Emergency Departments | CPAP VentilationItaly
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedObstructive Sleep Apnea | Acute Coronary SyndromeFrance
-
Fédération Française de PneumologieFederation of Medical SpecialtiesUnknownSleep Apnea Syndromes | High Cardiovascular RiskFrance
-
Kyoto University, Graduate School of MedicineCompleted
-
University of ZurichCompletedObstructive Sleep ApnoeaSwitzerland
-
Sociedad Española de Neumología y Cirugía TorácicaSocietat Catalana de PneumologiaCompletedObstructive Sleep Apnea | NormotensiveSpain